This is a discussion on TA148: Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Lung cancer (non-small-cell) - bevacizumab (terminated appraisal). It links to the ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
|
|||
|
The summary for the published technology appraisal on Lung cancer (non-small-cell) - bevacizumab (terminated appraisal). It links to the published guidance and key documents.
More... |
![]() |
| Thread Tools | |
| Display Modes | |
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA147: Breast cancer (advanced & metastatic) - bevacizumab (terminated appraisal) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA162: Lung cancer (non-small-cell) - erlotinib | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA175: Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA184: Lung cancer (small-cell) - topotecan | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA184: Lung cancer (small-cell) - topotecan | industry_news | Updates from the Technology Assessment Authorities | 0 | 11-25-2009 01:08 AM |